Biblio

Found 8 results
Filters: Author is Vanderah, T W  [Clear All Filters]
2020
Thompson AL, Grenald SA, Ciccone HA, BassiriRad N, Niphakis MJ, Cravatt BF, Largent-Milnes TM, Vanderah TW.  2020.  The Endocannabinoid System Alleviates Pain in a Murine Model of Cancer-Induced Bone Pain.. J Pharmacol Exp Ther. 373(2):230-238.
2017
Moutal A, Dustrude ET, Largent-Milnes TM, Vanderah TW, Khanna M, Khanna R.  2017.  Blocking CRMP2 SUMOylation reverses neuropathic pain.. Mol Psychiatry.
Sandweiss AJ, McIntosh MI, Moutal A, Davidson-Knapp R, Hu J, Giri AK, Yamamoto T, Hruby VJ, Khanna R, Largent-Milnes TM et al..  2017.  Genetic and pharmacological antagonism of NK1 receptor prevents opiate abuse potential.. Mol Psychiatry.
2013
Largent-Milnes TM, Brookshire SW, Skinner DP, Hanlon KE, Giuvelis D, Yamamoto T, Davis P, Campos CR, Nair P, Deekonda S et al..  2013.  Building a better analgesic: multifunctional compounds that address injury-induced pathology to enhance analgesic efficacy while eliminating unwanted side effects.. J Pharmacol Exp Ther. 347(1):7-19.
Lozano-Ondoua AN, Symons-Liguori AM, Vanderah TW.  2013.  Cancer-induced bone pain: Mechanisms and models.. Neurosci Lett. 557 Pt A:52-9.
2011
Tumati S, Roeske WR, Largent-Milnes TM, Vanderah TW, Varga EV.  2011.  Intrathecal PKA-selective siRNA treatment blocks sustained morphine-mediated pain sensitization and antinociceptive tolerance in rats.. J Neurosci Methods. 199(1):62-8.
2010
Largent-Milnes TM, Yamamoto T, Nair P, Moulton JW, Hruby VJ, Lai J, Porreca F, Vanderah TW.  2010.  Spinal or systemic TY005, a peptidic opioid agonist/neurokinin 1 antagonist, attenuates pain with reduced tolerance.. Br J Pharmacol. 161(5):986-1001.
Tumati S, Roeske WR, Largent-Milnes T, Wang R, Vanderah TW, Varga EV.  2010.  Sustained morphine-mediated pain sensitization and antinociceptive tolerance are blocked by intrathecal treatment with Raf-1-selective siRNA.. Br J Pharmacol. 161(1):51-64.